### 1 Effect of experimental hookworm infection on insulin resistance in people at risk of

### 2 Type 2 Diabetes: a randomized, placebo-controlled trial

3

### Authors and affiliations 4

- 5 Doris R. Pierce<sup>1</sup>, Malcolm McDonald<sup>1</sup>, Lea Merone<sup>2</sup> Luke Becker<sup>1</sup>, Fintan Thompson<sup>1,3</sup>,
- 6 Chris Lewis<sup>2</sup>, Matthew A. Field<sup>1,4,5</sup>, Tony Rahman<sup>6</sup>, John Croese<sup>1</sup>, Alex Loukas<sup>1</sup>, Robyn
- McDermott<sup>1,3</sup>, Paul R. Giacomin<sup>1</sup> 7

8

- 9 <sup>1</sup>Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine,
- 10 James Cook University, Cairns, QLD, Australia
- 11 <sup>2</sup>College of Health Sciences, James Cook University, Cairns, QLD, Australia
- <sup>3</sup>University of South Australia, Adelaide, SA, Australia 12
- 13 <sup>4</sup>College of Public Health, Medical & Vet Sciences, James Cook University, Cairns, QLD,
- 14 Australia
- 15 <sup>5</sup>Immunogenomics Laboratory, Garvan Institute of Medical Research, Darlinghurst, NSW,
- 16 Australia
- 17 <sup>6</sup>The Department of Gastroenterology and Hepatology, The Prince Charles Hospital,
- 18 Brisbane, QLD, Australia
- 19 \*Correspondence: Paul Giacomin, James Cook University, Cairns Campus
- 20 AITHM Building E5, 16-88 McGregor Road, Smithfield, QLD, Australia 4878
- 21 ph: +61-7-42321868, paul.giacomin@jcu.edu.au
- 22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 23 ABSTRACT

24 The reduced prevalence of insulin resistance and type 2 diabetes (T2D) in countries with 25 endemic parasitic worm infections suggests a protective role for worms against metabolic disorders, however clinical evidence has been non-existent. This 2-year randomized 26 27 controlled trial of hookworm infection in 40 people at risk of T2D involved treatment with 28 either 20 or 40 Necator americanus third-stage larvae (L3) or Placebo. Primary outcome 29 was safety, with homeostatic model assessment of insulin resistance (HOMA-IR), fasting 30 blood glucose (FBG), and body mass being the key metabolic outcomes. Adverse events 31 were more frequent in hookworm-treated participants, where 44% experienced transient 32 gastrointestinal symptoms. FBG and HOMA-IR were significantly lowered in both 33 hookworm-treated groups at 1-year, and body mass was significantly lowered after L3-20 34 treatment at 2-years. Overall, hookworm infection was well tolerated in people at risk of T2D, 35 and were associated with improved insulin resistance, warranting further exploration of the 36 benefits of hookworms on metabolic health.

38 Metabolic syndrome (MetS) represents a collection of related metabolic conditions, including dysregulated lipid homeostasis, hypertension, insulin resistance, and abdominal obesity, 39 40 that increase the likelihood of developing chronic diseases such as type 2 diabetes mellitus (T2D) and cardiovascular disease<sup>1</sup>. T2D is a complex illness associated with hyperglycemia; 41 42 long-term and costly medical care is usually required to prevent complications. The 43 prevalence of T2D is increasing globally, with more than half a billion adults already 44 diagnosed<sup>2</sup>; hence there is a pressing need to develop new preventative approaches to limit 45 the burden of T2D on individuals and health systems.

46

The soaring global prevalence of T2D is undoubtedly related to lifestyle factors such as an 47 48 energy-dense diet and a sedentary lifestyle. In this context, the detrimental role of systemic. 49 low-grade inflammation in promoting insulin resistance is well-established<sup>3</sup>. In lean adipose tissue, there exists an anti-inflammatory environment, including regulatory T cells, 50 51 eosinophils, and alternatively activated macrophages that are stimulated by Type 2 52 cytokines such as interleukin (IL)-4, IL-5, and IL-13. Conversely, in obesity there is a proinflammatory milieu involving Type 1 cytokines such as IFNy and TNF, classically-activated 53 macrophages<sup>4</sup>, and a dysregulated gut microbiome <sup>5</sup>. This biased Type-1 immune response 54 55 aggravates insulin resistance through stress-activated kinases that target intermediates in the insulin-signaling pathway<sup>6</sup>. It follows that maintaining the systemic and adipose-specific 56 57 inflammatory balance in favor of a Type 2 or regulatory immune response is a rational 58 approach to limiting the inflammatory cascade and preventing the ensuing insulin resistance seen in metabolic disease. 59

60

Parasitic helminths (worms) co-evolved with humans and remain endemic in regions of the
world with less metabolic and inflammatory diseases <sup>7-10</sup>. Helminth infections are associated
with Type 2 immune responses such as eosinophilia, elevated IL-4, -5 and -13, Type-2

64 innate lymphoid cell responses, and modulation of the gut microbiome<sup>11</sup>. Emerging evidence supports the hypothesis that eradicating worms from industrialized regions may 65 have partly contributed to the increased prevalence of immune-mediated diseases such as 66 T2D<sup>8,12</sup>. For example, human epidemiological studies suggest that the presence of helminth 67 68 infections is associated with lessened inflammatory responses and improved glucose homeostasis<sup>12 13 10</sup>, and two systematic reviews and meta-analyses concluded that adults 69 with previous or current worm infection typically enjoy improved metabolic function<sup>14</sup> <sup>15</sup>. 70 71 While cross-sectional studies support the idea of a protective role for worms in metabolic 72 disease, they did not establish causality.

73

74 Recent deworming studies provided some causative evidence. The removal of worms from previously-infected individuals was associated with increased insulin resistance (elevated 75 homeostatic model assessment for insulin resistance, HOMA-IR)<sup>16</sup>, elevated serum insulin 76 77 and glucagon <sup>17</sup>, enhanced hyperglycaemia and risk of metabolic disease <sup>18</sup>, and worsened 78 blood lipid profiles <sup>19</sup>. Experimental mouse studies corroborate findings from human studies, 79 where infection with various worm species caused improvements in metabolic indices, Type 80 2 immune responses, and alterations to the gut microbiome <sup>20 21-24</sup>. However, to date, there 81 have been no studies in humans testing whether a controlled helminth infection is safe, can 82 improve metabolic health, and potentially prevent progression to T2D.

83

Previously, we and others have established the safety of infecting human volunteers with low doses of hookworms in various inflammatory diseases <sup>25-27</sup>. While none of these studies investigated metabolic health outcomes, it is well reported that hookworms elicit Type 2 and regulatory immune responses <sup>26</sup> and changes in the microbiome <sup>28</sup> that may be beneficial in the context of T2D. The primary aim of this randomized, double-blinded, placebo-controlled Phase 1b clinical trial was to establish the safety, tolerability, and potential metabolic

- 90 benefits of experimental infection with infective third-stage larvae (L3) of the human 91 hookworm Necator americanus in otherwise healthy adults at risk of developing metabolic
- 92 syndrome and T2D. Based on previous animal and deworming studies, we hypothesized
- 93 that hookworm infection would be safe and improve the primary metabolic outcome for the
- 94 study, HOMA-IR, which assesses longitudinal changes in insulin sensitivity that correlate
- well with estimates derived via the euglycaemic clamp<sup>29</sup>. 95

#### 97 RESULTS

#### 98 Study population

99 We conducted a 2-year Phase Ib randomised, double-blinded, placebo-controlled trial of 100 experimental hookworm infection (either 20 or 40 infective third-stage larvae, L3) in 101 otherwise healthy people at risk of T2D (Figure 1A). Recruiting progressed between 102 January 2018 and June 2020, with 85 potential participants meeting screening criteria, of 103 which 41 met the inclusion/exclusion criteria to proceed to randomization (4 short of the 104 recruitment target). Forty-four participants were excluded due to not having elevated 105 baseline HOMA-IR (n=27), not responding to communication (n=11) or excluded 106 medications or medical conditions (n=6) (Figure 1B). One participant who qualified for the 107 study dropped out prior to their baseline visit. Forty participants were randomised and 108 constituted the intention-to-treat (ITT) population (Table 1). Thirteen participants were 109 allocated to receive Placebo treatment, 14 to receive a dose of 20 hookworm larvae (L3-20) 110 and 13 to receive a dose of 40 hookworm larvae (L3-40). (Figure 1B). The majority of 111 participants (85%) were of Caucasian descent. Baseline age and HOMA-IR were higher in 112 the L3-20 group. One participant who was randomized into the Placebo group 113 unintentionally received an L3-20 treatment due to a labelling error. This participant was 114 included in the Placebo group for the ITT analysis but in the L3-20 group for per-protocol 115 analyses.

		Allocation	117
	Placebo (n= 13)	L3-20 (n=14)	L3-40 (n= 13)
Median age (range), years	35 (27-50)	43 (30-45)	36 (27-49) 118
Female, n (%)	10 (75%)	10 (73%)	10 (77%)
Body mass, median (IQR), kg	106 (90-121)	104 (89-126)	<sup>102 (90-130)</sup> <b>119</b>
Height, median (IQR), cm	168 (162-176)	164 (158-174)	168 (165-178)
BMI, median (IQR), kg/m <sup>2</sup>	37 (33-41)	38 (33-46)	36 (32-41)
Waist Circumference, median (IQR), cm	111 (102-122)	111 (103-116)	111(105-123) 20
HOMA-IR, median (IQR), units	2.2 (2.0-2.8)	3.0 (2.3-3.5)	2.4 (2.0-3.2)

116 Table 1: Intention to Treat Baseline Characteristics for all Randomised Participants (n=40)

### 123 Adverse events (AEs)

124 The study's primary outcome was the safety and tolerability of hookworm treatment, defined 125 by the frequency and severity of AEs. A total of 20 AEs and no serious AEs were reported 126 (Table 2). As expected, gastrointestinal (GI) adverse events occurred in the L3-20 and L3-127 40 treatment groups (**Table 2**), consistent with the worms arriving in the gut and attaching 128 to the intestinal wall. These AEs were experienced by 44% of hookworm-treated participants 129 and included bloating, nausea, vomiting, constipation, diarrhoea, epigastric upset, hungry feeling, stomach cramps and abdominal pain, which were typically mild-moderate and 130 131 resolved without medical intervention. One GI-related symptom (5%) was recorded as 132 severe, and three warranted early removal of the participants from the study (1 in the L3-20 133 group, 2 in the L3-40 group) and provision of deworming medication. Two of these 134 individuals recovered promptly after deworming, while symptoms in one participant 135 persisted, indicating their symptoms may have been unrelated to hookworm. No GI-related AEs occurred in the Placebo group. No participant developed anaemia (Supplementary 136 137 Figure 1), the primary clinical effect of moderate to heavy hookworm infection. AEs deemed 138 unrelated to worm infection were reported across all groups and included one case each of 139 concussion, laryngitis, appendicectomy, gynaecological procedure, salmonella infection 140 acquired overseas, breast cancer diagnosis, erythema, and dermatitis. The chi-square test for trend revealed a significant linear trend for AEs,  $\chi^2$  (1, N = 40) = 3.846, p = 0.049 with 141 142 more AEs occurring in the hookworm treatment groups compared to the Placebo group, as 143 anticipated based on studies in other patient populations <sup>30</sup>.

- 144
- 145
- 146
- 147
- 148

### 149 Table 2. Summary of the number of adverse events (AE) and proportions of participants experiencing

#### 150 at least one AE, classified by AE type and symptom severity

		Total Number AEs (Proportion with >1 AE)						
	Placebo (n=13)	L3-20 (n=14)		L3-40 (n=13)		Combined hookworm (n=27)		
Any AE	3 (15%)	9 (50%)		8 (46%)		17 (48%)		
Unrelated	3 (15%)	4 (21%)		1 (8%)		5 (19%)		
Hookworm-related (GI)	0	5 (36%)	5 (36%)			12 (44%)		
		Mild	1	Mild	2	Mild	3	
	Severity of GI symptoms:	Moderate	4	Moderate	4	Moderate	8	
		Severe	0	Severe	1	Severe	1	

#### 152 Study Progression and well-being

Rates of trial completion and participant mood and well-being were secondary safety 153 154 outcomes. The CONSORT Flow Diagram (Figure 1B) and Kaplan-Meier curve (Figure 1C) 155 detail study progression. Early dropouts (0-6 months) included the 3 participants with GI 156 symptoms and one participant in the L3-20 group that was removed from the study at 3 157 months due to an unrelated cancer diagnosis (Figure 1B). Reasons for early terminations 158 later in the study included 4 participants moving away (Placebo n=2, L3-20 n=1, L3-40 n=1), 1 for undisclosed personal reasons (L3-20), 3 for failure to respond to communication or 159 160 testing exhaustion (Placebo n=2, L3-40 n=1), and 4 for starting medication (L3-20, n=1) or 161 undergoing gastric sleeve surgery (Placebo n=1, L3-20 n=2) that could interfere with the 162 trial outcomes. Four participants (Placebo n=1, L3-20 n= 1, L3-40 n=1) missed one 163 evaluation visit each but completed the remaining evaluation visits. Twenty-four of the 40 randomised participants completed the trial, including 8 (62%) in the Placebo, 7 in the L3-164 20 (50%), and 9 in the L3-40 group (69%). The difference in study completion between 165 166 groups was not significant (Figure 1C, Log-rank test for trend, p=0.832). Monitoring of 167 participant mood and depressive state via the Patient Health Questionnaire-9 (PHQ-9) 168 questionnaire revealed that median scores in the Placebo group remained relatively stable 169 throughout (Table 3). There was a trend for reduced median PHQ-9 scores (suggestive of 170 improved mood) compared to baseline in both hookworm treatment groups at all evaluation 171 visits; however, Mixed-effects model analyses and Kruskal-Wallis tests did not detect any 172 significant differences over time or between groups, even when the active hookworm 173 treatment groups were combined (Mann-Whitney test) (Table 3).

174

#### Table 3. Patient Health Questionnaire scores in each treatment group 175

	Patient Health Questionnaire (PHQ)-9 scores, Median and IQR (							
	Baseline	6 months	12 months	18 months	24 months			
DI 1	7	5	6	6	9 <b>177</b>			
Placebo	4-14 ( <i>n</i> = 12)	3-8 ( <i>n</i> = 12)	1-13 ( <i>n</i> = 9)	3-9 (n = 8)	2-16 ( <i>n</i> = 7)			
1.2.20	8	4	4	3	<sup>3</sup> 178			
L3-20	2-11 ( <i>n</i> = 13)	2-7 ( $n = 12$ )	2-7 ( $n = 11$ )	1-9 (n = 11)	1-6 (n = 8)			
L3-40	10	9	5	6.5	<sup>4</sup> 179			
L3-40	5-12 ( <i>n</i> = 11)	3-12 ( <i>n</i> = 11)	3-8 ( <i>n</i> = 10)	2-10 ( <i>n</i> = 8)	2-9 (n = 9)			
Combined Heelmoore	8	5	4	6	4			
Combined Hookworm	3-12 (n = 24)	2-11 ( $n = 23$ )	2-7 $(n = 21)$	1-9 (n = 19)	2-8 $(n = 17)$			

181

#### 182 Analysis of potential confounding variables: diet and exercise habits

183 Participants completed regular questionnaires to record any changes in diet and exercise 184 habits that could confound results. Analysis of the diet guestionnaire (PREDIMED) revealed 185 no significant inter-cohort differences or longitudinal changes in PREDIMED score in any 186 treatment group (Supplementary Figure 2A). Similarly, analysis of the exercise habits of 187 participants by quantifying their median numbers of metabolic equivalent of tasks (METs) 188 per week revealed no significant changes within groups from baseline and no significant 189 differences in median absolute METs/week or changes in METs/week between groups at 190 any time point (Supplementary Figure 2B).

191

#### 192 **Evaluation of hookworm establishment**

193 Hookworm infection is associated with the presence of hookworm eggs in stool and 194 peripheral blood eosinophilia. As expected, eosinophil counts remained stable in the 195 Placebo cohort (Figure 2A), and faecal samples were negative for hookworm ova (Figure 196 **2C**). In both the L3-20 and L3-40 groups, eosinophil counts were significantly elevated from 197 baseline by 6 months (L3-20 p = 0.047, L3-40 p= 0.002, Tukey's posthoc test) (Figure 2A). 198 Of the 28 hookworm-treated participants, five faecal samples were unavailable for qPCR 199 testing due to early dropout or inability to deliver a faecal sample. Twenty-one of the 23

participants (91%) tested positive for *N. americanus* ova (Figure 2C), and the two
 participants that tested negative still displayed robust increases in eosinophil counts (Figure 202
 2B).

203

## 204 **Primary metabolic outcome: Insulin resistance (HOMA-IR)**

We undertook a per-protocol analysis of metabolic outcome measures to account for the Placebo participant who received hookworm treatment in error. Data collected from the 4 participants described in the Study Progression section who, at 18 or 24 months, were retrospectively discovered to have undertaken gastric sleeve surgery or began taking metformin were excluded from the analysis. Data from one L3-20 participant whose insulin (47 mU/L), glucose (12.4 mmol/L) and HOMA-IR (26 units) values at 6 months were well beyond normal ranges and inconsistent with fasting were also excluded.

212

213 The trial's primary metabolic outcome was the effect of hookworm treatment versus placebo 214 on insulin resistance, as assessed by changes in HOMA-IR. Median HOMA-IR values in the 215 Placebo group fluctuated between improved and worsened from the baseline value of 2.2 216 [2.0-2.6], reaching a maximum of 2.9 [1.8-4.2] at 12 months, corresponding to a median 217 increase of 0.8 units [-0.7 to 2.3] (Table 4 and Figure 3A). In contrast, median HOMA-IR 218 value in the L3-20 group was significantly lowered from the baseline value of 3.0 [2.3-3.6] 219 to as low as 1.6 [0.9-3.0] at 18 months (p=0.028 Tukey's post-hoc test). Median change in 220 HOMA-IR values in the L3-20 group was significantly different from Placebo at 12 months 221 (p=0.039, Kruskal Wallis), with a reduction of 1.1 units [-1.5 to -0.5] from the baseline value. 222 Similar trends toward lowered HOMA-IR values were observed in the L3-40 group at 6 223 months (-0.5 units [-1.2 to 0.2]) and 12 months (-0.4 units [-1.4 to 0.9]); however, these 224 changes were not statistically different from Placebo at any evaluation visit. Since 225 significance tests depend greatly on sample size, and numbers in all groups were low, we

- 226 calculated the effect sizes of treatment versus control to measure the treatment effect
- 227 independent of participant numbers. Effect sizes for HOMA-IR changes in the L3-20 versus
- Placebo group were medium at 6 months (*d*=0.76) and large at 12 months (*d*=1.24), 18 228
- 229 months (*d*=1.01) and 2 years (*d*=1.03). For the L3-40 group, effect sizes were moderate at
- 230 6 months (d=0.55) and 12 months (d=0.75) and negligible at 18 months (d=0.25) and 2
- 231 years (*d*=-0.15) (**Supplementary Table 1**).

			Н	OMA-IR (units), M	edian and IQI	R (n)			
	baseline	6 months	Δ6 mo.	12 months	Δ12 mo.	18 months	Δ18 mo.	24 months	Δ24 mo.
Placebo	2.2	2.6	-0.2	2.9	+0.8	2.0	-0.2	2.0	-0.3
riacebo	2.0-2.6 ( <i>n</i> = 12)	2.1-3.1 $(n = 12)$	-0.6 to 1.0	1.8-4.2 ( <i>n</i> = 9)	-0.7 to 2.3	1.6-3.8 ( <i>n</i> = 8)	-0.9 to 2.3	1.4-2.7 $(n = 6)$	-0.8 to 0.6
L3-20	3.0	2.3	-0.6	1.8	-1.1*	1.6 #	-1.5	2.1	-0.8
L3-20	2.3-3.5 ( <i>n</i> = 13)	1.5-3.2 ( <i>n</i> = 11)	1.9 to -0.1	1.7-2.5 $(n = 11)$	-1.5 to -0.5	0.9-3.0 ( <i>n</i> = 8)	-1.8 to -0.1	1.5-2.3 (n = 7)	-1.3 to -0.4
1.2.40	2.4	2.1	-0.5	2.4	-0.4	2.5	-0.3	1.5	-0.5
L3-40	2.1-3.0 $(n = 11)$	1.8-2.6 ( <i>n</i> = 11)	-1.2 to 0.2	1.7-3.2 (n = 10)	-1.4 to 0.9	1.9-3.1 ( <i>n</i> = 8)	-0.4 to 0.4	1.0-4.8 ( <i>n</i> = 9)	-1.2 to 1.1
			Fasting b	lood glucose (mmo	l/L), Median a	nd IQR (n)			
	4.8	5.0	0.0	4.8	+0.3	4.6	-0.1	4.0	-0.8
Placebo	4.5-5.1 ( <i>n</i> = 12)	4.0-5.3 ( <i>n</i> = 12)	-0.5 to 0.5	4.4-5.4 ( <i>n</i> = 9)	-0.4 to 0.8	4.2-5.3 ( <i>n</i> = 8)	-0.7 to 0.6	3.1-5.1 (n = 6)	-1.9 to 0.6
12.20	5.2	4.5 #	-0.7	4.2	-0.9	4.5	-0.5	4.7	-0.6
L3-20	4.7-5.6 ( <i>n</i> = 13)	4.0-5.1 ( <i>n</i> = 11)	-1.0 to -0.3	3.6-5.6 ( <i>n</i> = 11)	-1.1 to 0.6	4.2-4.7 ( <i>n</i> = 8)	-1.0 to 0.1	3.9-4.8 ( <i>n</i> = 7)	-1.2 to -0.4
L3-40	5.3	4.3 #	-0.7 *	4.1#	-1.0 *	4.5	-0.4	4.3 #	-0.6
L3-40	4.9 <b>-</b> 5.4 ( <i>n</i> = 11)	4.0-5.3 ( <i>n</i> = 11)	-1.0 to -0.6	3.7-4.9 ( <i>n</i> = 10)	-1.4 to -0.7	4.1-5.1 ( <i>n</i> = 8)	-1.2 to 0.0	4.0-4.9 (n = 9)	-1.1 to -0.4
			Fasting b	olood insulin (mmol	/L), Median a	nd IQR (n)			
Placebo	11	12	+1	12	+2	11	0	11	+1
Flacebo	9-12 ( <i>n</i> = 12)	10-15 ( <i>n</i> = 12)	-2 to 4	8-19 ( <i>n</i> = 9)	-3 to 10	8-16 ( <i>n</i> = 8)	-3 to 8	10-14 ( <i>n</i> = 6)	-1 to 2
1.2.20	13	10	-2	10	-4 *	9 #	-5	10	-3
L3-20	12-16 ( <i>n</i> = 13)	7-14 ( <i>n</i> = 11)	-7 to 1	9-14 ( <i>n</i> = 11)	-5 to -3	5-14 ( <i>n</i> = 8)	-7 to -1	7-12 ( $n = 7$ )	-4 to 1
1.2.40	10	10	-1	12	+1	12	+2	8	-1
L3-40	9-13 ( <i>n</i> = 11)	9-15 ( <i>n</i> = 11)	-3 to 2	9-18 ( <i>n</i> = 10)	-4 to 6	10-17 ( <i>n</i> = 8)	-1 to 3	6-22 ( <i>n</i> = 9)	-5 to 8

Table 4. Absolute values and changes in HOMA-IR, fasting blood glucose and insulin in each treatment group

# Significantly different to baseline. \*Significantly different to Placebo

## Supplementary Table 1. HOMA-IR change effect sizes at each evaluation visit

	Placebo	L3-20	L3-20 vs Placebo	L3-40	L3-40 vs Placebo	
6 months	$0.18 \pm 1.13$	$-0.74 \pm 1.29$	$d = 0.76^{M}$	$-0.42\pm1.05$	$d = 0.55^{M}$	
omontus	<i>n</i> = 12	<i>n</i> = 11	u = 0.70	n = 11	<i>u</i> = 0.55	
12 months	$0.99 \pm 2.0$	$\textbf{-0.91} \pm 0.85$	$d = 1.24^{\text{L}}$	$\textbf{-0.26} \pm 1.26$	$d = 0.75^{M}$	
	<i>n</i> = 9	<i>n</i> = 11	a = 1.24	<i>n</i> = 10		
19 4h	$0.79\pm2.47$	$\textbf{-1.09} \pm 0.88$	$d = 1.01^{\text{L}}$	$0.29 \pm 1.31$	1-0.25 \$	
18 months	<i>n</i> = 8	<i>n</i> = 8	$a = 1.01^{-2}$	<i>n</i> = 8	$d = 0.25^{8}$	
24 41	$-0.13 \pm 0.77$	$-1.13 \pm 1.14$	$d = 1.03^{\text{L}}$	$\textbf{-0.04} \pm 1.79$	<i>d</i> = -0.15	
24 months	n = 6	n = 7	$a = 1.03^{-2}$	<i>n</i> = 9		

M, medium effect size; L, large effect size; S, small effect size.

## 258 Metabolic outcomes: Fasting blood glucose, insulin and glycated haemoglobin

259 Median FBG levels (mmol/L) in the Placebo group were stable throughout and did not significantly deviate from their starting values (p=0.132, Mixed-effects model analysis) 260 261 (Table 4 and Figure 3B). In contrast, median FBG levels were significantly reduced from 262 baseline levels after 6 months in both the L3-20 (baseline: 5.2 [4.7-5.6] to 6 months: 4.5 263 [4.0-5.1]; p=0.045) and L3-40 groups (baseline: 5.3 [4.9-5.4] to 6 months; 4.3 [4.0-5.3]; 264 p=0.016). Similar significant reductions in FBG were seen in the L3-40 group at 12 months 265 (p=0.007) and 2 years (p=0.015) compared to baseline; however reductions in the L3-20 266 group were not statistically significant at any other time point (12 months p=0.184, 18 267 months *p*=0.069, 2 years *p*=0.052). Median changes in FBG levels in the L3-20 treatment group were not significantly different to Placebo at any time point, but changes in the L3-40 268 269 group were significantly different to Placebo at 6 months (-0.7 in L3-40 compared to 0.0 in 270 Placebo; p=0.027) and 12 months (-1.0 in L3-40 compared to +0.3 in Placebo; p=0.024).

271

272 Fasting insulin levels (mU/L) were stable in the Placebo group throughout the study, ranging 273 from a baseline of 11 [9-12] to a maximum of 12 [10-15] at 6 months (Table 4 and Figure 274 **3C**). There were no longitudinal changes in insulin levels in the L3-40 group at any time 275 point and no significant differences compared to Placebo. Insulin levels in the L3-20 group 276 were consistently lowered from the baseline level of 13 [12-16] to a minimum of 9 [5-14] at 277 18 months (p=0.043 compared to baseline), with reductions from baseline values reaching 278 statistical significance compared to Placebo at 12 months (-4.0 in L3-20 compared to +2.0 279 in placebo; p=0.02).

280

Levels of glycated haemoglobin (HbA1cIFCC, mmol/mol) displayed an upward trend at all evaluation visits compared to baseline in the Placebo group, ranging from a baseline value

of 32 [30-33] mmol/mol to a maximum of 35 [33-37] at 2 years (Supplementary Table 2).

- Values in the L3-20 group were stable near the baseline value of 33 [30-35] throughout,
- while values in the L3-40 group experienced similar upward trends to the Placebo group,
- with values significantly higher than baseline at 18 months (*p*=0.027).

Supplementary Table 2. Absolute values and changes in glycated haemoglobin (HbA1c	/IFCC) in each treatment group
---	--------------------------------

HbA1C IFCC (mmol/mol), Median and IQR (n)									
	baseline	6 months	Δ6 mo.	12 months	Δ12 mo.	18 months	Δ18 mo.	24 months	Δ24 mo.
Placebo	32	34	+1	34	+2	33	+3	35	+4
	30-33 ( <i>n</i> = 12)	30-36 ( <i>n</i> = 12)	0 to 3	30-37 ( <i>n</i> = 9)	0 to 4	30-36 ( <i>n</i> = 8)	0 to 4	33-37 ( <i>n</i> = 6)	1 to 5
1 2 20	33	32	0	32	0	33	+1	33	+2
L3-20	31-35 ( <i>n</i> = 13)	30-34 ( <i>n</i> = 11)	-1 to 1	31-35 ( <i>n</i> = 11)	-1 to 1	32-36 ( <i>n</i> = 8)	0 to 2	32-37 ( <i>n</i> = 7)	1 to 4
1.2.40	32	31	+1	33	+3	34 #	+4	32	+2
L3-40	29-34 ( <i>n</i> = 11)	30-35 ( <i>n</i> = 11)	0 to 3	32-35 ( <i>n</i> = 10)	1 to 4	33-37 $(n = 8)$	2 to 7	31-37 ( <i>n</i> = 9)	2 to 5

# Significantly different to baseline

### 296 Secondary metabolic outcomes: Body mass and blood lipid profile

297 Median body mass and Body Mass Index (BMI) in the Placebo group remained stable 298 throughout (Table 5, Figure 4 and Supplementary Figure 3). While there were no 299 statistically significant differences in body mass or BMI in the L3-20 or L3-40 groups 300 compared to Placebo (Table 5), body mass and BMI in the L3-20 group tended to be lower 301 than their baseline values at all evaluation visits, with significant reductions in body mass 302 and BMI in the L3-20 group at 18 months (p=0.019 for body mass, p=0.028 for BMI) and 2 303 years (p=0.031 for body mass and p=0.032 BMI). This corresponded to a median reduction 304 in body mass of approximately 5kg at both time points in the L3-20 group (Table 5 and 305 Figure 4) and a reduction in BMI of 2.2 units and 2.4 units at 18 months and 2 years, 306 respectively (Table 5 and Supplementary Figure 2). No significant longitudinal changes in 307 body mass or BMI were evident in the L3-40 group.

308

309 Analysis of blood lipid profile revealed that median levels of total cholesterol, triglycerides, 310 high-density lipoprotein, low-density lipoprotein and total cholesterol/HDL ratio remained 311 relatively stable in the Placebo group at all time points, with only a statistically significant 312 reduction in LDL (p=0.009) and total cholesterol at 18 months (p=0.037) (**Supplementary** 313 **Tables 3 and 4**). In both the L3-20 and L3-40 groups, there were no longitudinal changes 314 in any of these parameters compared to baseline and no significant differences compared 315 to Placebo other than elevated LDL (p=0.019) and total cholesterol (p=0.038) at 18 months 316 in the L3-40 group compared to Placebo (Supplementary Tables 3 and 4).

	Body mass (kg), Median and IQR (n)								
	baseline	6 months	Δ6 mo.	12 months	Δ12 mo.	18 months	Δ18 mo.	24 months	Δ24 mo.
Placebo	105	107	+2	99	0	105	-1	106	+2
riacebo	89-115 ( <i>n</i> = 12)	91-115 ( <i>n</i> = <i>12</i> )	-4 to 4	90-113 ( <i>n</i> = 8)	-4 to 4	89-119 ( <i>n</i> = 8)	-8 to 9	91-118 ( <i>n</i> = 6)	-4 to 5
12.20	103	101	-3	104	-1	93 #	-5	93 #	-5
L3-20	86-131 ( <i>n</i> = 13)	82-134 ( <i>n</i> = 12)	-3 to 1	90-133 ( <i>n</i> = 11)	-5 to 1	76-120 $(n = 8)$	-12 to -3	77-124 ( $n = 7$ )	-10 to -1
1.2.40	102	102	-1	106	+1	109	+2	108	+4
L3-40	90-131 ( <i>n</i> = 11)	86-130 ( <i>n</i> = 11)	-2 to 1	91-129 ( <i>n</i> = 10)	-2 to 6	100-136 ( <i>n</i> = 8)	-1 to 8	94-133 ( <i>n</i> = 9)	-2 to 6
				BMI (kg/m²), Med	ian and IQR (r	1)			
Placebo	37	37	+0.7	36	+0.1	39	-0.3	38	+0.8
Flacebo	33-40 ( <i>n</i> = 12)	33-41 ( <i>n</i> = <i>12</i> )	-1.2 to 1.2	31-41 ( <i>n</i> = 8)	-1.5 to 1.5	32-41 ( <i>n</i> = 8)	-3.0 to 3.2	32-40 ( <i>n</i> = 6)	-1.9 to 1.7
L3-20	37	37	-0.5	39	-0.2	35 #	-2.2	33 #	-2.4
L3-20	33-46 ( <i>n</i> = 13)	32-49 ( <i>n</i> = 12)	-1.3 to 1.5	34-44 ( <i>n</i> = 11)	-1.3 to 0.1	31-41 ( <i>n</i> = 8)	-4.2 to -1	30-41 ( <i>n</i> = 7)	-2.7 to -0.5
1.2.40	36	36	-0.1	35	+0.3	39	+0.6	38	+0.9
L3-40	33-40 ( <i>n</i> = 11)	31-40 $(n = 11)$	-0.7 to 0.5	33-39 ( <i>n</i> = 10)	-0.8 to 2.3	34-40 $(n = 8)$	-0.2 to 2.3	33-41 ( <i>n</i> = 9)	-0.7 to 2.1

Table 5. Body mass and Body Mass Index (BMI) absolute values and changes in each treatment group

# Significantly different to baseline. \*Significantly different to Placebo

Supplementary Table 3. Absolute values and changes in serum cholesterol, high-density lipoprotein (HDL) and cholesterol/HDL ratio in each

treatment group			

			Total c	holesterol (mmol/L	a), Median and	IQR (n)			
	baseline	6 months	Δ6 mo.	12 months	Δ12 mo.	18 months	Δ18 mo.	24 months	Δ24 mo
	5.4	4.9	-0.4	4.8	-0.4	4.9	-0.6 #	5.0	-0.2
Placebo	4.9-6.3 ( <i>n</i> = 12)	4.4-6.0 ( <i>n</i> = 12)	-0.7 to 0.0	4.45.4 ( <i>n</i> = 9)	-0.6 to -0.1	4.3-5.8 ( <i>n</i> = 8)	-1.1 to -0.1	4.5-5.3 ( <i>n</i> = 6)	-0.6 to 0
L3-20	5.2	5.1	-0.3	5.0	-0.2	5.1	-0.2	4.9	-0.2
	4.6-6.3 ( <i>n</i> = 13)	3.9-5.9 ( <i>n</i> = 12)	-0.6 to -0.2	4.2-5.6 ( <i>n</i> = 11)	-0.7 to 0.5	4.5-5.7 ( <i>n</i> = 10)	-0.4 to 0.4	3.9-6.8 ( <i>n</i> = 18)	-0.5 to 0
L3-40	5.4	6.0	+0.7	5.6	+0.2	5.7	+0.4 *	5.3	-0.1
L3-40	4.9-5.5 ( <i>n</i> = 11)	4.9-6.3 ( <i>n</i> = 11)	-0.2 to 0.9	4.8-5.7 ( <i>n</i> = 10)	-0.2 to 0.3	4.6-6.1 (n = 8)	-0.2 to 0.6	4.3-5.8 ( <i>n</i> = 9)	-0.8 to 0
			ŀ	IDL (mmol/L), Me	dian and IQR	(n)			
Placebo	1.2	1.1	-0.1	1.2	0.0	1.2	-0.1	1.2	0.0
Placedo	1.1-1.4 ( <i>n</i> = 12)	1.0-1.3 ( <i>n</i> = 12)	-0.1 to 0.0	1.1-1.3 (n = 9)	0.0 to 0.1	1.1-1.6 (n = 8)	-0.2 to 0.2	1.0-1.7 $(n = 6)$	-0.3 to 0
12.00	1.2	1.3	-0.1	1.1	0.0	1.2	-0.2	1.1	+0.1
L3-20	1.0-1.5 ( <i>n</i> = 13)	1.0-1.4 ( <i>n</i> = 12)	-0.2 to -0.1	1.0-1.4 ( <i>n</i> = 11)	-0.1 to 0.0	1.0-1.3 ( <i>n</i> = 10)	-0.2 to 0.0	1.0-1.7 $(n = 8)$	-0.1 to 0
L3-40	1.3	1.3	0.0	1.3	0.0	1.2	-0.1	1.1	-0.1
L3-40	1.1-1.5 $(n = 11)$	1.1-1.5 ( <i>n</i> = 11)	-0.2 to 0.2	1.1-1.3 ( <i>n</i> = 10)	-0.1 to 0.1	1.1-1.3 (n = 8)	-0.2 to -0.1	1.0-1.4 (n = 9)	-0.3 to 0
			Total cl	holesterol/HDL rat	io, Median and	l IQR (n)			
Placebo	4.4	4.0	-0.1	4.0	-0.4	3.9	-0.2	3.9	+0.1
riacedo	3.8-5.2 ( <i>n</i> = 12)	3.8-4.9 ( <i>n</i> = 12)	-0.3 to 0.3	3.5 to 4.3 ( <i>n</i> = 9)	-0.6 to -0.2	3.3-4.6 (n = 8)	-0.7 to 0.3	3.3-5.1 (n = 6)	-0.6 to 0.
1 2 20	4.1	4.2	+0.2	4.2	-0.1	4.3	+0.3	4.2	-0.2
L3-20	3.8-4.9 ( <i>n</i> = 13)	3.7-4.9 ( <i>n</i> = 12)	0.0 to 0.3	3.7-5.3 (n = 11)	-0.2 to 0.5	3.6-5.6 ( <i>n</i> = 10)	-0.3 to 1.1	3.3-5.0 (n = 8)	-0.6 to 0.4
1 2 40	4.0	4.4	+0.5	4.5	+0.1	4.8	+0.5	4.3	+0.2
L3-40	3.7-4.9 ( <i>n</i> = 11)	4.0-4.7 ( <i>n</i> = 11)	-0.2 to 0.8	3.9-5.1 ( <i>n</i> = 10)	-0.4 to 0.8	4.1-5.0 ( <i>n</i> = 8)	0.0 to 0.9	4.0-5.4 ( <i>n</i> = 9)	-0.1 to 0.

# Significantly different to baseline. \*Significantly different to Placebo

			Trigl	ycerides (mmol/L),	Median and I	QR (n)			
	baseline	6 months	Δ6 mo.	12 months	Δ12 mo.	18 months	Δ18 mo.	24 months	Δ24 mo.
	1.4	1.4	+0.2	1.3	0.0	1.4	+0.3	1.8	+0.7
Placebo	0.9-2.0 ( <i>n</i> = 12)	1.0-2.0 ( <i>n</i> = 12)	-0.4 to 0.6	0.9-1.6 (n = 9)	-0.2 to 0.3	1.0-1.9 (n = 8)	-0.2 to 0.5	1.4-2.9 (n = 6)	0.4 to 1.4
L3-20	1.3	1.3	-0.2	1.2	-0.1	1.4	0.0	1.1	+0.1
	0.9-1.8 ( <i>n</i> = 13)	0.8-1.7 ( <i>n</i> = 12)	-0.3 to 0.2	1.0-1.5 ( <i>n</i> = 11)	-0.4 to 0.2	0.8-2.5 ( <i>n</i> = 10)	-0.2 to 0.8	0.9 <b>-</b> 1.9 ( <i>n</i> = 8)	-0.3 to 0.3
1.2.40	1.4	1.3	-0.2	1.8	+0.1	1.7	-0.1	1.3	+0.1
L3-40	0.8-2.0 ( <i>n</i> = 11)	1.0-2.7 ( <i>n</i> = 11)	-0.4 to 0.9	1.0-2.6 ( <i>n</i> = 10)	-0.4 to 0.6	1.1-1.9 ( <i>n</i> = 8)	-0.2 to 0.7	0.9-2.1 ( <i>n</i> =9)	-03 to 0.3
			I	LDL (mmol/L), Me	dian and IQR	(n)			
Placebo	3.5	3.1	-0.2	2.9	-0.3	2.9#	-0.6	2.7	-0.6
riacedo	3.0-4.4 ( <i>n</i> = 12)	2.6-3.9 ( <i>n</i> = 12)	-0.7 to 0.0	2.6-3.4 $(n = 9)$	-0.8 to -0.1	2.5-3.5 ( <i>n</i> = 8)	-0.8 to -0.3	2.6-3.2 (n = 6)	-0.7 to 0.2
1 2 20	3.3	3.4	-0.4	3.2	-0.1	3.1	-0.3	3.1	-0.2
L3-20	2.9-4.3 ( <i>n</i> = 13)	2.5-3.8 ( <i>n</i> = 12)	-0.6 to 0.0	2.7-3.7 ( <i>n</i> = 11)	-0.6 to 0.6	2.6-3.9 ( <i>n</i> =10)	-0.5 to 0.5	2.1-4.1 $(n = 8)$	-0.4 to 0.3
X 2 40	3.4	3.4	+0.3	3.2	+0.2	3.8	+0.5*	3.1	+0.1
L3-40	2.6-3.6 ( <i>n</i> = 11)	3.0-4.0 ( <i>n</i> = 11)	-0.3 to 1.3	3.0-3.8 ( <i>n</i> = 10)	-0.3 to 0.4	2.9-4.0 $(n = 8)$	0.0 to 0.6	2.7-3.7 $(n = 9)$	-0.5 to 0.5
									303

# Significantly different to baseline. \*Significantly different to Placebo

#### 368 DISCUSSION

369 Over recent decades, helminth infection has emerged as a potential approach for treating allergic and autoimmune disorders, as well as metabolic disorders such as MetS and 370 T2D<sup>15,21,27</sup>. Until now, a potential supportive role for worms in metabolic health has relied on 371 372 animal studies and human cross-sectional or deworming studies that could not infer 373 causality. The present study provides the first reported controlled-trial clinical evidence for 374 the beneficial effect of helminth infection in metabolic disease. Infection with low doses of 375 hookworms caused significantly reduced measures of glucose homeostasis (lowered 376 HOMA-IR and fasting blood glucose) compared to pre-infection and Placebo treatment, 377 which was associated with modest body mass reductions. Diet and physical activity changes 378 could not explain these improvements. While the study was relatively small and needs to be 379 validated by larger follow-up studies, the results provide critical proof of principle that 380 hookworms and/or the biological changes they invoke in their human hosts are a safe and 381 potentially beneficial intervention for improving determinants of metabolic health and 382 preventing the development of T2D.

383

384 The primary outcome of this Phase Ib study was to determine the safety and tolerability of 385 hookworm infection in people at risk of developing T2D. While hookworm infection was 386 associated with a higher incidence of gastrointestinal AEs, these were anticipated during the time that hookworms established in the gut<sup>30</sup> and were typically mid-moderate and 387 388 resolving. Three of the 28 hookworm-treated participants displayed GI symptoms that 389 warranted deworming, and symptoms resolved promptly in two. The third did not improve 390 after deworming, suggesting their symptoms were unrelated to hookworm infection. Overall, 391 the safety profile of hookworm treatment in people at risk of T2D is similar to that in other diseases <sup>30</sup>. 392

393

394 In the current study, hookworm infection was associated with improved insulin resistance, 395 consistent with previous mouse or natural human helminth infection studies <sup>7,21,31</sup>. Lowered 396 HOMA-IR was most apparent in the group that received 20 hookworms and was most 397 pronounced at 18 months, with a reduction in median HOMA-IR from 3.0 units at baseline 398 (consistent with pre-diabetic insulin resistance) to 1.6 units at 18 months (a healthy level). 399 The large Cohen's *d* effect sizes in the L3-20 group highlight the statistical and clinical 400 significance of this sustained improvement in metabolic health. Interestingly, the improvements in HOMA-IR in the group that received 40 worms were less dramatic, despite 401 402 similar trends in reduced HOMA-IR at 6 and 12 months. Both the L3-20 and L3-40 groups 403 showed similar reductions in fasting blood glucose compared to Placebo throughout the 404 study, but only the L3-20 group displayed sustained reductions in insulin. By the later stages 405 of the study, all results from the L3-40 group were comparable to Placebo, indicating that a 406 higher worm dose did not vield superior improvements in insulin resistance. This is 407 somewhat counter-intuitive, but larger clinical trials are required to clarify the optimal dose 408 of hookworms. One factor that may partially explain why participants in the L3-20 cohort 409 responded better to treatment was that pre-trial median age and HOMA-IR were higher; 410 hence there was greater potential for improvements. Future clinical trials designed to 411 demonstrate efficacy should stratify participants based on high and low baseline HOMA-IR.

412

In conversations with potential participants during recruitment and screening, it was evident that a powerful motivator to enrol was the prospect of body mass reductions, as documented in mouse<sup>20-22,24</sup> or natural human helminth infection studies<sup>7,24,31,32</sup>. We noted modest reductions in body mass and BMI in the L3-20 group; however, body mass reductions were not consistent for all hookworm-treated participants, possibly due to the relatively low worm burdens compared to those seen in animal studies or natural infections. This caused disappointment for some people, who then elected to pursue gastric sleeve surgery despite

improvements in HOMA-IR. Most participants were less concerned and continued with
unabated enthusiasm. Bar one, all hookworm-treated participants that completed the study
opted to retain their worms, and the sole person who dewormed did so in preparation for a
medical procedure.

424

425 Interestingly, hookworm infection did not improve blood lipid profiles in contrast to what may have been expected based on previous studies <sup>9,10,13,24,32</sup>. A potential explanation could lie 426 427 in the different helminth species used in the current trial. Previous studies noting improved 428 blood lipid markers included cross-sectional and deworming studies of infections with multiple soil-transmitted helminths <sup>32</sup> and previous and current schistosomiasis <sup>9,10,13,24</sup> but 429 430 not hookworm infection alone. Results from a 2019 systematic review and meta-analysis 431 suggested that different helminth species may have different efficacy in altering lipid and glucose homeostasis<sup>15</sup>. The authors postulated that the liver-specific residence of 432 433 Schistosoma spp. compared to intestinal helminths could facilitate greater metabolic 434 improvements in schistosomiasis. Future helminth challenge studies such as ours that instead use single-sex infections with schistosome parasites <sup>33</sup> may validate this hypothesis. 435

436

437 The study had several limitations, with the major shortcoming being the small sample sizes 438 that limited our ability to make firm conclusions. This was further curbed by the long duration 439 of the study and attrition of participants in all groups after the 12-month time point. Since T2D takes many years to manifest, future studies will need to follow up with participants for 440 441 longer periods. Ideally, this would be combined with repeated doses of hookworms to 442 maintain a chronic infection and monitoring of the associated immune response. Such 443 studies could include a deworming arm to determine if an active hookworm infection is 444 required for longer-term benefits and could use HbA1c IFCC as a longer-term primary 445 outcome measure of improved glycaemic control.

446 Further, participant selection bias limited the generalizability of our findings. Most participants were of Caucasian descent, and it is unclear if different populations, such as 447 448 people of Asian descent or Australian First Nations people, who disproportionately suffer from MetS and T2D <sup>34</sup>, would experience similar improvements. Lastly, within the scope of 449 450 this study, we could not attain a mechanistic understanding of how and why hookworm 451 infection caused improvements in insulin resistance. Type 2 immune responses and eosinophils are known to influence metabolism<sup>20,35</sup>, so it remains plausible that they 452 contributed to stimulating this pathway. Better understanding of the beneficial biological 453 454 effects of hookworms in the context of MetS may identify novel therapeutic strategies that 455 could mimic the actions of the live hookworm (e.g. immune-modifying or microbiome 456 therapies) or may pinpoint factors that are excreted/secreted by hookworms that could be 457 produced as novel biologic therapies <sup>36</sup>.

458

In conclusion, the hygiene hypothesis<sup>8,12</sup> provides a persuasive explanation for the increasing prevalence of inflammatory and metabolic disorders in populations with a low prevalence of helminth infections. The present study is the first to demonstrate that experimental infection with low hookworm doses is safe and leads to clinically significant improvements in glucose homeostasis in people at risk of MetS and T2D. Results from this proof of concept study will inform the further development of novel preventative interventions in humans at risk of T2D.

#### 466 **METHODS**

#### 467 Study design and regulatory approvals

468 Between January 2018 and April 2022, we conducted a 2-year Phase Ib randomised, 469 double-blinded, placebo-controlled trial of experimental hookworm infection (either 20 or 40 470 infective third-stage larvae, L3) in otherwise healthy people at risk of T2D. The study included two clinical sites in Queensland, Australia (James Cook University Cairns and 471 Townsville campuses). The study designated C26 was approved on April 19<sup>th</sup> 2017 by the 472 473 Human Research Ethics Committee of James Cook University. The trial was registered with 474 the Australian New Zealand Clinical Trials Registry (ACTRN12617000818336). The clinical study protocol was published in 2019<sup>37</sup>. 475

476

#### 477 Participants and sample collection

478 Inclusion criteria: Otherwise healthy males and females aged 18-50 years with central 479 obesity (waist circumference> 90cm for women and >102cm for men) and increased insulin 480 resistance as assessed via abnormal HOMA-IR>2.12 or at least two other features of 481 metabolic syndrome determined at screening (blood pressure>135/85 mmHg, dyslipidaemia 482 or abnormal liver function tests). Exclusion criteria, in brief, included pregnancy, established 483 chronic disease, historical or current substance abuse, major allergies, known 484 immunodeficiency disorder, unstable asthma or taking medications likely to interfere with 485 study outcomes. Blood samples were taken at each 6-monthly visit into serum separator 486 tubes for serum analyses or heparin-coated tubes for complete blood count analysis 487 (Beckton Dickinson). Participants were asked to provide fresh faecal samples at each study 488 visit, which were frozen at -80°C for future analysis of the presence of hookworm eggs by 489 qPCR.

490

### 491 **Randomization and masking**

492 An initial recruitment target of 54 participants allowed for a dropout rate of 20%, leaving a desired recruitment target of 45 volunteers (15 in each treatment group) to participate in the 493 494 trial. Volunteers who met the eligibility criteria and had given informed consent were 495 randomly allocated on a 1:1:1 ratio according to a computer-generated sequence to one of 496 the three study arms: Placebo, 20x N. americanus L3 (L3-20) or 40x L3 (L3-40). Participants 497 and investigators were blinded to the treatment, other than the assigned producer of the 498 inocula (co-author L.B.).

499

#### 500 Preparation and administration of treatments

501 The inocula were prepared freshly as previously described <sup>38</sup>. Hookworm ova were collected 502 from two volunteer donors, initially infected in 2013 or 2018 with 5 N. americanus L3 from a 503 line donated by Professor David Pritchard (University of Nottingham). Visibly motile L3 were 504 individually selected for inclusion in the inocula, contained within 300 µl of de-ionised water. 505 Placebo inocula comprised 300 µl of de-ionised water containing approximately 2 µl of 506 Tabasco<sup>®</sup> sauce. The inoculation procedure involved dispensing the solution onto a non-507 absorbent dressing pad placed onto the participant's forearm. Two doses of inocula were 508 administered eight weeks apart, with L3-20 and L3-40 participants receiving 10x or 20x L3 509 on each occasion (Figure 1A). Hookworm infection status was monitored at baseline and 510 six months using gPCR on 1g of thawed and homogenised faecal samples, as described 511 previously <sup>39</sup>.

512

#### 513 **Outcome measures**

514 Safety assessments were conducted at each designated visit (Figure 1A) to identify adverse 515 events (AEs) and serious AEs and their suspected causality. Complete blood counts and

516 metabolic indices (glucose, insulin, HbA1c, liver function tests and lipids) were measured in 517 serum samples at an accredited Australian clinical pathology laboratory. HOMA-IR was 518 calculated by multiplying fasting blood glucose (mmol/L) by insulin (mU/L) values and 519 dividing by 22.5<sup>29</sup>. Blood pressure was monitored using automated blood pressure devices. 520 Height was measured using either a wall-mounted measuring tape or a stadiometer. Waist 521 circumference was measured using a flexible measuring tape. Body mass was recorded 522 using digital scales with a maximum capacity of 250kg. Body mass index (BMI) was 523 calculated by dividing mass in kg by height in meters squared.

524

## 525 Diet, physical activity, mood and depressive state monitoring

The 14-item self-administered Prevención con Dieta Mediterránea (PREDIMED) diet questionnaire was used to monitor changes in participants' diets throughout the trial  $^{40}$ . Using a scorecard, participants recorded their weekly physical activity, including type, duration, frequency, and intensity, which were combined into a single metric<sup>41</sup>, the metabolic equivalent of task (MET) per week (*MET x duration x frequency = METs/week*). To track changes in mood and depressive state, we used the validated Patient Health Questionnaire (PHQ)-9  $^{42}$ .

533

## 534 Statistical analyses

The chi-square test for trend was used to determine differences in the safety of hookworm infection, assessed by the proportions of AEs between each group. The Kaplan-Meier model was used to compare progression through the study, with associations between groups assessed using the Log-rank test statistic. Standard descriptive statistics were performed on all characteristics at baseline and each of the four evaluation visits (categorical variables: absolute and relative frequencies; numerical variables: mean and 95% confidence intervals

or median and interquartile range, dependent on data distribution). Normality testing indicated that most data were not normally distributed. Thus, Kruskal-Wallis with Dunn's multiple comparisons tests were used to detect inter-cohort differences in absolute values and changes or Mann-Whitney tests where hookworm groups were combined (PHQ-9). For significant results in tests with posthoc analyses, the adjusted *p*-value is reported. For test results stated as not significant, *p* was > 0.05. To calculate effect sizes (Cohen's *d*) for HOMA-IR changes, the following equation was used:

548  $d = M_1 - M_2/\delta_{pooled}$  ( $\delta_{pooled}$ , pooled standard deviation) with  $\delta_{pooled} = \sqrt{[(\delta_1^2 + \delta_2^2)/2]}$ 549 (http://www.bwgriffin.com/gsu/courses/edur9131/content/EffectSizeBecker.pdf).

A research team member and an independent monitor reviewed data from each participant to identify and address missing information. To account for missing data, this study followed the method prescribed in Jakobsen et al.<sup>43</sup>. Specifically, as missing data exceeded 40%, no imputation was undertaken, and results were interpreted in the context of this limitation. The mixed-effects model (which allows missing values) with Tukey's multiple comparisons tests was applied for longitudinal analyses with missing values. Statistical analyses were performed in GraphPad Prism 9.0.

557

- 558 Role of the funding source
- 559 The funders had no role in the design or conduct of the study

560

#### 561 **ACKNOWLEDGEMENTS**

562 The work was funded by the Far North QLD Hospital Foundation (PG, RM, AL), Australian 563 Institute of Tropical Health and Medicine (RM, PG, AL), Australian National Health and 564 Medical research Council (NHMRC) Senior Principal Research Fellowship (AL), Program 565 Grant (AL), Advance Queensland Fellowship (PG) and an Australian Research Training 566 Program Stipend (DP). Funders had no role in the design or conduct of the study. We also 567 thank Rebecca Traub, Sze Fui Hii and Patsy Zendajas (University of Melbourne) for 568 assistance with hookworm qPCR assays, Sally McDonald, Lynne Reid, Melissa Piontek, 569 Tyler Gilstrom, Melissa Campbell and Geraldine Buitrago for assistance with clinical trial 570 operations.

### 571 **AUTHOR CONTRIBUTIONS**

- 572 Conceptualization: RM, AL, TR, JC, and PG. Data analysis: DP, FT, RM, PG. Funding: DP,
- 573 AL, RM, PG, MF. Investigation: DP, MM, LM, LB, CL, AL, RM, PG. Methodology: DP, MM,
- 574 LB, JC, AL, RM, PG, MF. Project administration: DP, MM, LM, FT, CL, RM, PG. Writing -
- 575 original draft. DP and PG. Writing – review & editing: All authors

### 577 **DECLARATION OF INTERESTS**

- 578 P.R.G and A.L are founders and shareholders of Macrobiome Therapeutics, which is
- 579 developing hookworm-derived proteins as drugs for treating inflammatory conditions.

## 581 **REFERENCES**

- Despres, J. P. *et al.* Abdominal obesity and the metabolic syndrome: Contribution to
   global cardiometabolic risk. *Arterioscler. Thromb. Vasc. Biol.* 28, 1039-1049 (2008).
   <a href="https://doi.org:10.1161/ATVBAHA.107.159228">https://doi.org:10.1161/ATVBAHA.107.159228</a>
- 585 2 International Diabetes Federation. *IDF Diabetes Atlas 10th Edition 2021*,
  586 <a href="https://diabetesatlas.org/">https://diabetesatlas.org/</a>> (2022).
- 587 3 Xu, H. *et al.* Chronic inflammation in fat plays a crucial role in the development of
  588 obesity-related insulin resistance. *J. Clin. Invest.* **112**, 1821-1830 (2003).
  589 <u>https://doi.org:10.1172/JCI19451</u>
- 590 4 Hotamisligil, G. S. Inflammation and metabolic disorders. *Nature* **444**, 860 (2006).
- 591 5 Qin, J. *et al.* A metagenome-wide association study of gut microbiota in type 2 592 diabetes. *Nature* **490**, 55-60 (2012). https://doi.org:10.1038/nature11450
- 593 6 Wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. *J. Clin. Invest.*594 **115**, 1111-1119 (2005). <u>https://doi.org:10.1172/JCI200525102</u>
- 5957Wiria, A. E. *et al.* Infection with soil-transmitted helminths Is associated with increased596insulinsensitivity.*PLoSOne***10**, e0127746 (2015).
- 597 <u>https://doi.org:10.1371/journal.pone.0127746</u>
- 598 8 Yazdanbakhsh, M., Kremsner, P. G. & van Ree, R. Allergy, parasites, and the 599 hygiene hypothesis. *Science* **296**, 490-494 (2002). 600 https://doi.org:10.1126/science.296.5567.490
- Shen, S. W. *et al.* The potential long-term effect of previous schistosome infection
  reduces the risk of metabolic syndrome among Chinese men. *Parasite Immunol.* 37,
  333-339 (2015). https://doi.org:10.1111/pim.12187
- Wolde, M. *et al.* Inverse Associations of Schistosoma mansoni Infection and
   Metabolic Syndromes in Humans: A Cross-Sectional Study in Northeast Ethiopia.

- 606 Microbiology Insights 12. 1178636119849934 (2019). https://doi.org:10.1177/1178636119849934 607
- 608 Loke, P. n., Lee, S. C. & Oyesola, O. O. Effects of helminths on the human immune 11 609 response and the microbiome. Mucosal Immunol. (2022). 610 https://doi.org:10.1038/s41385-022-00532-9
- 611 12 de Ruiter, K. et al. Helminths, hygiene hypothesis and type 2 diabetes. Parasite 612 Immunol. 39, e12404 (2017). https://doi.org:doi:10.1111/pim.12404
- 613 13 Mohamed, S. M. A., Saber, T., Taha, A. A., Roshdy, H. S. & Shahien, N. E. Relation
- 614 between Schistosome Past Infection and Metabolic Syndrome. J. Egypt. Soc. 615 Parasitol. 47, 137-143 (2017).
- 616 Tracev, E. F., McDermott, R. A. & McDonald, M. I. Do worms protect against the 14 617 metabolic syndrome? A systematic review and meta-analysis. Diabetes Res. Clin.
- Pract. 120, 209-220 (2016). https://doi.org:10.1016/j.diabres.2016.08.014 618
- 619 15 Rennie, C., Fernandez, R., Donnelly, S. & McGrath, K. C. The impact of helminth 620 infection on the incidence of metabolic syndrome: A systematic review and meta-
- 621 analysis. Front. Endocrinol. (Lausanne) 12, 728396 (2021). 622 https://doi.org:10.3389/fendo.2021.728396
- 623 16 Tahapary, D. L. et al. Effect of anthelmintic treatment on insulin resistance: A cluster-624 randomized, placebo-controlled trial in Indonesia. Clin. Infect. Dis. 65, 764-771 625 (2017). https://doi.org:10.1093/cid/cix416
- 626 Rajamanickam, A. et al. Metabolic consequences of concomitant Strongyloides 17 627 stercoralis infection in Type 2 diabetes mellitus. Clin. Infect. Dis. (2018). 628 https://doi.org:10.1093/cid/civ935
- 629 18 Muthukumar, R. et al. Effects of Opisthorchis viverrini infection on glucose and lipid 630 profiles in human hosts: A cross-sectional and prospective follow-up study from 631 Thailand. Parasitol. Int., 102000 (2019). https://doi.org:10.1016/j.parint.2019.102000

- Sanya, R. E. *et al.* The effect of helminth infections and their treatment on metabolic
  outcomes: Results of a cluster-randomised trial. *Clin. Infect. Dis.* (2019).
  https://doi.org:10.1093/cid/ciz859
- Wu, D. *et al.* Eosinophils sustain adipose alternatively activated macrophages
  associated with glucose homeostasis. *Science* 332, 243-247 (2011).
  https://doi.org:10.1126/science.1201475
- Hussaarts, L. *et al.* Chronic helminth infection and helminth-derived egg antigens
  promote adipose tissue M2 macrophages and improve insulin sensitivity in obese
  mice. *FASEB J.* 29, 3027-3039 (2015). https://doi.org:10.1096/fj.14-266239
- 641 22 Yang, Z. et al. Parasitic nematode-induced modulation of body weight and associated
- 642 metabolic dysfunction in mouse models of obesity. Infect. Immun. 81, 1905-1914
- 643 (2013). <u>https://doi.org:10.1128/IAI.00053-13</u>
- 644 23 Morimoto, M., Azuma, N., Kadowaki, H., Abe, T. & Suto, Y. Regulation of type 2
- diabetes by helminth-induced Th2 immune response. J. Vet. Med. Sci. 78, 1855-1864
- 646 (2017). <u>https://doi.org:10.1292/jvms.16-0183</u>
- 647 24 Duan, Q. et al. Population based and animal study on the effects of Schistosoma
- japonicum infection in the regulation of host glucose homeostasis. Acta Trop. **180**,
- 649 33-41 (2018). <u>https://doi.org:10.1016/j.actatropica.2018.01.002</u>
- 650 25 Croese, J. *et al.* Randomized, placebo controlled trial of experimental hookworm 651 infection for improving gluten tolerance in celiac disease. *Clinical and Translational*
- 652 *Gastroenterology* **11**, e00274 (2020).
- 653 https://doi.org:10.14309/ctg.00000000000274
- 654 26 Croese, J. *et al.* Experimental hookworm infection and gluten microchallenge
  655 promote tolerance in celiac disease. *J. Allergy Clin. Immunol.* **135**, 508-516 (2015).
  656 <u>https://doi.org:10.1016/j.jaci.2014.07.022</u>

- Tanasescu, R. *et al.* Hookworm Treatment for Relapsing Multiple Sclerosis: A
  Randomized Double-Blinded Placebo-Controlled Trial. *JAMA Neurol* (2020).
  https://doi.org:10.1001/jamaneurol.2020.1118
- Cantacessi, C. *et al.* Impact of experimental hookworm infection on the human gut
  microbiota. *The Journal of Infectious Diseases* **210**, 1431-1434 (2014).
  https://doi.org:10.1093/infdis/jiu256
- 662 <u>https://doi.org:10.1093/infdis/jiu256</u>
- Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling.
   *Diabetes Care* 27, 1487-1495 (2004). https://doi.org:10.2337/diacare.27.6.1487
- 665 30 Chapman, P. R. et al. Vaccination of human participants with attenuated Necator
- 666 americanus hookworm larvae and human challenge in Australia: a dose-finding study
- and randomised, placebo-controlled, phase 1 trial. Lancet Infect. Dis. (2021).
- 668 <u>https://doi.org:10.1016/S1473-3099(21)00153-5</u>
- 669 31 Chen, Y. *et al.* Association of previous schistosome infection with diabetes and 670 metabolic syndrome: A cross-sectional study in rural China. *J. Clin. Endocrinol.*
- 671 *Metab.* **98**, E283-E287 (2013). <u>https://doi.org:10.1210/jc.2012-2517</u>
- Wiria, A. E. *et al.* Relationship between carotid intima media thickness and helminth
  infections on Flores Island, Indonesia. *PLoS One* 8, e54855 (2013).
  https://doi.org:10.1371/journal.pone.0054855
- Langenberg, M. C. C. *et al.* A controlled human Schistosoma mansoni infection model
  to advance novel drugs, vaccines and diagnostics. *Nat. Med.* 26, 326-332 (2020).
- 677 <u>https://doi.org:10.1038/s41591-020-0759-x</u>
- 678 34 Diabetes Australia. Aboriginal and Torres Strait Islander People,
   679 <a href="https://www.diabetesaustralia.com.au/living-with-diabetes/aboriginal-and-torres-">https://www.diabetesaustralia.com.au/living-with-diabetes/aboriginal-and-torres-</a>
   680 strait-islanders/> (n.d.).

- Moyat, M., Coakley, G. & Harris, N. L. The interplay of type 2 immunity, helminth
  infection and the microbiota in regulating metabolism. *Clinical & Translational Immunology* 8, e01089 (2019). https://doi.org:10.1002/cti2.1089
- 684 36 Ryan, S. M., Eichenberger, R. M., Ruscher, R., Giacomin, P. R. & Loukas, A.
  685 Harnessing helminth-driven immunoregulation in the search for novel therapeutic
- 686 modalities. *PLoS Pathog* **16**, e1008508 (2020).
- 687 <u>https://doi.org:10.1371/journal.ppat.1008508</u>
- 688 37 Pierce, D. *et al.* Safety and tolerability of experimental hookworm infection in humans
  689 with metabolic disease: study protocol for a phase 1b randomised controlled clinical
- 690 trial. *BMC Endocr. Disord.* **19**, 136 (2019). <u>https://doi.org:10.1186/s12902-019-0461-</u>
- 691 <u>5</u>
- 692 38 Chapman, P. R. *et al.* The production of Necator americanus larvae for use in
  693 experimental human infection. *Parasites* & *Vectors* 15, 242 (2022).
  694 <u>https://doi.org:10.1186/s13071-022-05371-y</u>
- 695 39 Hii, S. F. *et al.* Development and evaluation of a multiplex quantitative real-time 696 polymerase chain reaction for hookworm species in human stool. *Am. J. Trop. Med.*
- 697 *Hyg.* **99**, 1186-1193 (2018). <u>https://doi.org:10.4269/ajtmh.18-0276</u>
- Martínez-González, M. A. *et al.* A 14-Item Mediterranean diet assessment tool and
   obesity indexes among high-risk subjects: The PREDIMED trial. *PLoS One* 7, e43134
- 700 (2012). <u>https://doi.org:10.1371/journal.pone.0043134</u>
- Ainsworth, B. E. *et al. The Compendium of Physical Activities Tracking Guide*,
   <<u>https://sites.google.com/site/compendiumofphysicalactivities/</u>> (2011).
- Levis, B., Benedetti, A., Thombs, B. D. & Collaboration, D. E. S. D. Accuracy of
  Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression:
  individual participant data meta-analysis. *BMJ* 365, 11476 (2019).
- 706 <u>https://doi.org:10.1136/bmj.I1476</u>

- Jakobsen, J. C., Gluud, C., Wetterslev, J. & Winkel, P. When and how should multiple 707 43 708 imputation be used for handling missing data in randomised clinical trials - a practical 709 guide with flowcharts. BMC Med. Res. Methodol. 17, 162 (2017). 710 https://doi.org:10.1186/s12874-017-0442-1
- 711
- 712

#### 713 **FIGURE LEGENDS**

714 Figure 1. Study time line, CONSORT flow diagram and study progression. (A) After screening and informed consent, participants were allocated to receive either placebo (chilli 715 716 pepper solution) or a total of 20 (L3-20) or 40 (L3-40) N. americanus hookworm larvae 717 delivered to the skin over 2 occasions, at month 0 and month 2. Participants underwent 718 evaluation visits every 6 months, where physical and vitals exams were undertaken, adverse 719 events were reviewed, and biological samples and questionnaires were collected for 720 analysis of safety, pathology, well-being, diet and exercise habits. (B) CONSORT chart 721 showing flow of patients through the clinical trial, and reasons for early termination. (C) 722 Kaplan Meier analysis of rates of trial continuation (%) in each group during the 2-year study.

723

724 Figure 2. Evaluation of establishment of hookworm infections. (A) Peripheral blood 725 eosinophil counts (median ± IQR) at each evaluation visit, shaded area indicates normal 726 range. (B) Heat map displaying eosinophil counts the 6 month visit (peak eosinophilia) in 727 each participant and correlation with the (C) detection of hookworm eggs in feces by gPCR 728 (Hookworm patency). Some samples were unable for analysis due to droppoing out prior to 729 the 6-month visit.

730

731 Figure 3. Effect of experimental hookworm infection on insulin resistance (HOMA-IR), 732 fasting blood glucose and insulin. Changes in the (A) Homeostatic model assessment of 733 insulin resistance (HOMA-IR, units), (B) Fasting blood glucose and (C) fasting blood insulin 734 levels from baseline values at each 6-monthly evaluation visit. Violin plots display each 735 individual data point, median and IQR. Dotted vertical line indicates baseline levels (0 change). \*Significant difference to placebo, # Significant difference to baseline value. 736

737

738	Figure 4. Impact of experimental hookworm infection on body mass. Changes in
739	participant's body mass (kg) from baseline values at each 6-monthly evaluation visit. Violin
740	plots display each individual data point, median and IQR. Dotted vertical line indicates
741	baseline levels (0 change). # Significant difference to baseline value.

742

- Supplementary Figure 1. Hookworm infection was not associated with anemia. Blood
  hemoglobin concentration at each evaluation visit (median and IQR), shaded area indicates
- combined normal range for males and females.

746

747 Supplementary Figure 2. Diet (PREDIMED score) and Physical Activity remained

relatively stable in all groups throughout the study. (A) PREDIMED total scores in each


749 treatment group at each evaluation visit (median and IQR). (B) Physical activity (Metabolic


750 Equivalents of task, METs) per week assessed at each evaluation visit (median and IQR).


751


## 752 Supplementary Figure 3. Impact of experimental hookworm infection on body mass

index (BMI). Changes in participant's body mass index (kg/m<sup>2</sup>) from baseline values at each
6-monthly evaluation visit. Violin plots display each individual data point, median and IQR.
Dotted vertical line indicates baseline levels (0 change). # Significant difference to baseline
value.











# **SUPPLEMENTARY FIGURE 1**



# **SUPPLEMENTARY FIGURE 2**



# **SUPPLEMENTARY FIGURE 3**

